Date: 2016-11-18
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Gilead Sciences (USA - CA)
Product: GLPG2737
Action
mechanism: C2 corrector.
Disease: cystic fibrosis
Therapeutic area: Rare diseases - Genetic diseases
Country: The Netherlands
Trial details:
Latest
news: * On November 28, 2016, Galapagos reported the initiation of a Phase 1 study in healthy volunteers with GLPG2737, a novel C2 corrector drug for cystic fibrosis. The aim of the Phase 1 study is to evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG2737. The randomized, double-blind, placebo controlled, single centre study is being conducted in at least 64 healthy volunteers in the Netherlands. In the first part of the study, single ascending doses will be evaluated. In the second part, multiple ascending doses will be administered daily for 14 days. Topline results from this Phase 1 study with GLPG2737 are expected in the second quarter of 2017. Galapagos now intends to initiate a patient evaluation of a triple combination therapy by mid-2017.
Initiation of the Phase 1 study triggers a $10 million milestone payment from AbbVie.
